Our multidisciplinary lab focuses on developing novel therapies and drug delivery systems based on nanotechnology and functional biomaterials. By studying key processes in the tumor microenvironment and employing an integrative approach that combines bioengineering, nanomedicine, and theoretical models, we rationally design selective nanotherapies to maximize drug efficacy while minimizing off-target effects.

We develop advanced 3D ex vivo cell models for tumor-on-a-chip applications. Using patient-derived samples and a flow device for precision medicine, this platform enables the study of the activity and toxicity of anti-cancer drugs and nanotherapies for personalized nanomedicine.